Cover Image

Management of chronic myeloid leukemia in 2025

Chronic myeloid leukemia (CML) has an annual incidence of approximately two cases per 100,000. The reduction in annual mortality from 10%-20% to 1% with BCR::ABL1 tyrosine kinase inhibitors (TKIs) has resulted in an increased prevalence in the United States of an estimated 150,000 cases in 2025. Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Kantarjian, Hagop (Author) , Breccia, Massimo (Author) , Haddad, Fadi G. (Author) , Hehlmann, Rüdiger (Author) , Issa, Ghayas C. (Author) , Malhotra, Hemant (Author) , Nicolini, Franck Emmanuel (Author) , Sasaki, Koji (Author) , Stenke, Leif (Author) , Jabbour, Elias (Author)
Format: Article (Journal)
Language:English
Published: 15 July 2025
In: Cancer
Year: 2025, Volume: 131, Issue: 14, Pages: 1-18
ISSN:1097-0142
DOI:10.1002/cncr.35953
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cncr.35953
Verlag, lizenzpflichtig, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35953
Get full text
Author Notes:Hagop Kantarjian MD, Massimo Breccia MD, Fadi G. Haddad MD, Rüdiger Hehlmann MD, Ghayas C. Issa MD, Hemant Malhotra MD, Franck Emmanuel Nicolini MD, Koji Sasaki MD, PhD, Leif Stenke MD, Elias Jabbour MD

MARC

LEADER 00000naa a2200000 c 4500
001 1935457101
003 DE-627
005 20250909075253.0
007 cr uuu---uuuuu
008 250909s2025 xx |||||o 00| ||eng c
024 7 |a 10.1002/cncr.35953  |2 doi 
035 |a (DE-627)1935457101 
035 |a (DE-599)KXP1935457101 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kantarjian, Hagop  |d 1952-  |e VerfasserIn  |0 (DE-588)138403872  |0 (DE-627)602054966  |0 (DE-576)307451240  |4 aut 
245 1 0 |a Management of chronic myeloid leukemia in 2025  |c Hagop Kantarjian MD, Massimo Breccia MD, Fadi G. Haddad MD, Rüdiger Hehlmann MD, Ghayas C. Issa MD, Hemant Malhotra MD, Franck Emmanuel Nicolini MD, Koji Sasaki MD, PhD, Leif Stenke MD, Elias Jabbour MD 
264 1 |c 15 July 2025 
300 |a 18 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Erstmals veröffentlicht: 5. Juli 2025 
500 |a Gesehen am 09.09.2025 
520 |a Chronic myeloid leukemia (CML) has an annual incidence of approximately two cases per 100,000. The reduction in annual mortality from 10%-20% to 1% with BCR::ABL1 tyrosine kinase inhibitors (TKIs) has resulted in an increased prevalence in the United States of an estimated 150,000 cases in 2025. This translates into a worldwide estimated prevalence of approximately 5 million cases, and hence the need to make TKIs available and affordable to all patients. The four main goals of CML therapy are to (1) improve survival; (2) achieve a durable deep molecular response, which may lead to a treatment-free remission status; (3) reduce short- and long-term side effects; and (4) provide good treatment value. Today, the six approved BCR::ABL1 TKIs, five in frontline therapy (imatinib, dasatinib, bosutinib, nilotinib, and asciminib) and all six in later line therapy (including ponatinib), fulfill in one form or another these requirements. Third-generation TKIs that target the ABL1 kinase domain (olverembatinib and ELVN-001) or the myristoyl pocket (TGRX-678 and TERN-701) are under development. Allogeneic hematopoietic stem cell transplantation is a one-time, cost-effective, curative treatment in patients with CML resistant to second-generation TKIs, which is perhaps surprisingly underused in 2025, given the high enthusiasm for it before the development of TKIs. However, serious complications, such as graft-vs-host disease, or death could occur. This review summarizes relevant information concerning the management of CML in 2025, and addresses some CML treatment pathways that became entrenched in the management of CML in the first 15-20 years of TKI experience, which may need to be revisited. 
650 4 |a chronic myeloid leukemia (CML) 
650 4 |a cost 
650 4 |a frontline 
650 4 |a tyrosine kinase inhibitor (TKI) 
700 1 |a Breccia, Massimo  |e VerfasserIn  |4 aut 
700 1 |a Haddad, Fadi G.  |e VerfasserIn  |4 aut 
700 1 |a Hehlmann, Rüdiger  |d 1941-  |e VerfasserIn  |0 (DE-588)1037003489  |0 (DE-627)751737879  |0 (DE-576)390939463  |4 aut 
700 1 |a Issa, Ghayas C.  |e VerfasserIn  |4 aut 
700 1 |a Malhotra, Hemant  |e VerfasserIn  |4 aut 
700 1 |a Nicolini, Franck Emmanuel  |e VerfasserIn  |4 aut 
700 1 |a Sasaki, Koji  |e VerfasserIn  |4 aut 
700 1 |a Stenke, Leif  |e VerfasserIn  |4 aut 
700 1 |a Jabbour, Elias  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Cancer  |d New York, NY : Wiley-Liss, 1948  |g 131(2025), 14 vom: Juli, Artikel-ID e35953, Seite 1-18  |h Online-Ressource  |w (DE-627)271350334  |w (DE-600)1479932-7  |w (DE-576)078590884  |x 1097-0142  |7 nnas  |a Management of chronic myeloid leukemia in 2025 
773 1 8 |g volume:131  |g year:2025  |g number:14  |g month:07  |g elocationid:e35953  |g pages:1-18  |g extent:18  |a Management of chronic myeloid leukemia in 2025 
856 4 0 |u https://doi.org/10.1002/cncr.35953  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35953  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20250909 
993 |a Article 
994 |a 2025 
998 |g 1037003489  |a Hehlmann, Rüdiger  |m 1037003489:Hehlmann, Rüdiger  |d 60000  |e 60000PH1037003489  |k 0/60000/  |p 4 
999 |a KXP-PPN1935457101  |e 4770287666 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"15 July 2025","dateIssuedKey":"2025"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"name":{"displayForm":["Hagop Kantarjian MD, Massimo Breccia MD, Fadi G. Haddad MD, Rüdiger Hehlmann MD, Ghayas C. Issa MD, Hemant Malhotra MD, Franck Emmanuel Nicolini MD, Koji Sasaki MD, PhD, Leif Stenke MD, Elias Jabbour MD"]},"person":[{"family":"Kantarjian","roleDisplay":"VerfasserIn","given":"Hagop","display":"Kantarjian, Hagop","role":"aut"},{"family":"Breccia","roleDisplay":"VerfasserIn","display":"Breccia, Massimo","role":"aut","given":"Massimo"},{"display":"Haddad, Fadi G.","role":"aut","given":"Fadi G.","roleDisplay":"VerfasserIn","family":"Haddad"},{"given":"Rüdiger","display":"Hehlmann, Rüdiger","role":"aut","family":"Hehlmann","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Issa","given":"Ghayas C.","role":"aut","display":"Issa, Ghayas C."},{"display":"Malhotra, Hemant","role":"aut","given":"Hemant","family":"Malhotra","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Nicolini","given":"Franck Emmanuel","role":"aut","display":"Nicolini, Franck Emmanuel"},{"family":"Sasaki","roleDisplay":"VerfasserIn","role":"aut","display":"Sasaki, Koji","given":"Koji"},{"display":"Stenke, Leif","role":"aut","given":"Leif","roleDisplay":"VerfasserIn","family":"Stenke"},{"role":"aut","display":"Jabbour, Elias","given":"Elias","family":"Jabbour","roleDisplay":"VerfasserIn"}],"physDesc":[{"extent":"18 S."}],"relHost":[{"title":[{"subtitle":"interdisciplinary international journal of the American Cancer Society","title":"Cancer","title_sort":"Cancer"}],"id":{"issn":["1097-0142"],"eki":["271350334"],"doi":["10.1002/(ISSN)1097-0142"],"zdb":["1479932-7"]},"disp":"Management of chronic myeloid leukemia in 2025Cancer","note":["Gesehen am 06.12.2011"],"language":["eng"],"origin":[{"dateIssuedKey":"1948","publisherPlace":"New York, NY","dateIssuedDisp":"1948-","publisher":"Wiley-Liss"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"131","issue":"14","text":"131(2025), 14 vom: Juli, Artikel-ID e35953, Seite 1-18","pages":"1-18","year":"2025","extent":"18"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"271350334","pubHistory":["1.1948 -"],"titleAlt":[{"title":"Cancer cytopathology"}]}],"recId":"1935457101","id":{"eki":["1935457101"],"doi":["10.1002/cncr.35953"]},"title":[{"title_sort":"Management of chronic myeloid leukemia in 2025","title":"Management of chronic myeloid leukemia in 2025"}],"note":["Erstmals veröffentlicht: 5. Juli 2025","Gesehen am 09.09.2025"]} 
SRT |a KANTARJIANMANAGEMENT1520 

Similar Items